MENLO PARK, Calif., February 25, 2014 -- Neodyne Biosciences, a medical device company focused on the development and commercialization of innovative tissue repair devices to promote healing and minimize scar formation, today announced a partnership with Strouse to scale production of its embrace® Advanced Scar Therapy devices, which mechanically deliver a uniform compressive strain to offload tension from a newly formed scar.
“embrace® is a powerful new technology for significantly reducing scarring and improving aesthetic outcomes following surgery,” said Bill Beasley, President of Neodyne Biosciences, “and as physician adoption and patient demand has increased, it’s critical for us to be in a position to meet that demand efficiently.”
“Our partnership with Neodyne is an exciting opportunity that is a direct result of our strategic focus on the Medical and Health Care market,” said Sue Chambers, President and CEO of Strouse, “We offer the ability to scale manufacturing and together we have the opportunity to get embrace® Advanced Scar Therapy into physician hands more quickly.”
Neodyne’s first product family, embrace® Advanced Scar Therapy, has received 510(k) clearance from the US Food and Drug Administration (FDA) and has been proven to significantly improve scar appearance in randomized, controlled studies.,2
About The Strouse Corporation
Strouse is a 3M Preferred Converter and a die cut adhesive manufacturer with over 25 years of industry experience. Serving the medical, automotive, military, appliance, and renewable energy industry, Strouse continues to innovate. With a quality management system currently registered to ISO 9001:2008 standards, Strouse not only has a commitment to quality but excellent customer service. A full team of design and development engineers allows Strouse to invest the necessary time and resources for each and every project.
About Neodyne Biosciences, Inc.
Neodyne Biosciences (www.neodynebio.com) is an evidence based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance. The company is developing stress-shielding devices capable of controlling the mechanical wound environment to ameliorate post-surgical scarring. Although the etiology remains unclear, mechanical forces such as surrounding skin tension and body movement have been demonstrated to increase fibrosis and scar formation. It is estimated that approximately 80 million major surgical procedures are performed in the United States each year and 230 million performed worldwide. Patient frustration with post-surgical scarring spans a variety of procedures with many seeking means of prevention and treatment.
Neodyne Investor Relations Contacts:
|Bill BeasleyPresident/COObbeasley@neodynebio.com||Michael FanucchiMarketingmfanucchi@neodynebio.com|
1Lim AF, et al. The embrace Device Significantly Decreases Scarring Following Scar Revision Surgery in a Randomized Controlled Trial. Plast Reconstr Surg. 2014;133:398-405.
2Data on File, #003.